We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!

5/The project was only possible because of collaboration with the Van Allen lab, talented co-first authors Julia Schiantarelli, Mouadh Benamar, Jihye Park. I am grateful to patients who donated biopsy material and funding sources, including @melanomaresearch.bsky.social @danafarbernews.bsky.social

4/and a reduced capacity to activate cytotoxic T cells.

3/Strikingly, we found resistance-associated mutations in SEC24C and SEC24D in 3 patients. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased Type I interferon production, antigen presentation

2/Over several years, we collected matched pre-treatment and post-resistance tumor biopsies in patients with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance.

1/Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors, most exhibit intrinsic or acquired resistance to these therapies.

Our paper on a new mechanism of resistance to immunotherapy in melanoma is now in print
@Cancer_Cell
with the @vanallenlab.bsky.social t.co/TCC4brc6yb